Providential Holdings

Providence Therapeutics is a Canadian clinical-stage biotechnology company specializing in the development of messenger RNA (mRNA) vaccines and therapeutics. Founded in 2013, the company initially focused on personalized cancer vaccines before pivoting to develop a COVID-19 vaccine candidate, PTX-COVID19-B, which has reached Phase 2 clinical trials. Providence utilizes a proprietary mRNA platform and has established significant manufacturing partnerships, notably with Everest Medicines for commercialization in Asian markets. The company's pipeline also includes mRNA-based treatments for various oncology indications and other infectious diseases. Providence is recognized as a pioneer in the Canadian mRNA landscape, being the first domestic company to advance an mRNA COVID-19 vaccine into human trials.